Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

NCT04948125 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Gastric Carcinoma

Interventions

DRUG: camrelizumab
DRUG: Apatinib Mesylate

Sponsor

Henan Cancer Hospital